Clinical trials in Caen – page 7

659 clinical trials in Caen, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Caen at a glance

659

clinical trials

Research sites3

Quick filters

659 trials in Caen

Open in trial search

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:DB-1303
Sponsor:BioNTech SE

Contact Research Centre

Hepatitis alcoholic

Recruiting

Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

Registered drug

Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Acetylcysteine
Sponsor:Centre Hospitalier Universitaire De Lille

Contact Research Centre

Bronchiolitis+1

Recruiting

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Nirsevimab
Sponsor:Centre Hospitalier Annecy Genevois

Contact Research Centre

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Pfizer Inc.

Contact Research Centre

Colorectal adenocarcinoma

Recruiting

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Association Gercor

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ambrisentan
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Cryoglobulinaemia

Recruiting

Study of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab

Registered drugNo placebo

Study of obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate rituximab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Craniocerebral injury

Recruiting

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Mannitol
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Breast cancer

Recruiting

Evaluating elacestrant alone or with leuprorelin in premenopausal women with early-stage hormone receptor positive breast cancer before surgery

Registered drugNo placebo

Evaluating elacestrant alone or with leuprorelin in premenopausal women with early-stage hormone receptor positive breast cancer before surgery

Registered drugNo placebo

France

Participants:18–64 years
Substances:Leuprorelin Acetate
Sponsor:Institut Gustave Roussy

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Caen

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on multiple cancer types including head and neck squamous cell carcinoma, endometrial cancer, and multiple myeloma. Studies evaluate novel therapeutic combinations and treatment strategies.

Advanced solid tumors
Hematological malignancies
Gastrointestinal cancers

Trials investigate targeted therapies and immunotherapy approaches for improved patient outcomes.

02 Infectious Disease Research

Studies examining prevention and treatment of respiratory infections, with focus on respiratory syncytial virus (RSV) in vulnerable populations. Investigation of novel antibiotics for prosthetic joint infections.

Viral infections
Bacterial infections
Preventive treatments

Research aims to develop effective preventive strategies and therapeutic interventions.

03 Cardiovascular Medicine

Research exploring treatments for heart failure prevention and management of cardiovascular conditions. Studies evaluate antiplatelet therapy strategies in elderly patients following interventional procedures.

Heart failure
Coronary interventions
Preventive cardiology

Focus on improving cardiovascular outcomes through innovative therapeutic approaches.

Back to France All countries